Heart Disease
Heart Disease Ongoing 2019

VESALIUS

To evaluate if treatment with additional cholesterol lowering medication reduces the risk of major cardiovascular events in patients at high cardiovascular risk.

Trial overview

Disease
Cardiovascular disease & care
Topic
VESALIUS
Eligibility criteria

To be considered for the study you must meet the following criteria:

  • Between 50-80 years (men) or 55-80 years (women) of age
  • LDL-Cholesterol ≥ 3 mmol/L or non-HDL ≥ 3.1 mmol/L after ≥ 2 weeks of optimised lipid lowering therapy
  • Evidence of either significant coronary artery disease, atherosclerotic cerebrovascular disease, peripheral arterial disease or diabetes mellitus
  • Have at least one high risk feature of family history of premature coronary artery disease, familial hypercholesterolaemia, current smoker, ≥ 65 years of age or menopause before 40 years of age
Study details

Your participation in this study would be for a minimum of 4 years.   

You will be seen in the clinic for a Screening and Day 1 visit and then return to the clinic every 4 months for drug dispensation. During these visits, you will also be asked about your health andmedications. 

You will be reimbursed for travel and study expenses. 

Sign up to this clinical trial here.

Doctors

Dr David B Cross

MBBS, FRACP, FCSANZ

General cardiologist

Works at 4 centres.

Dr Jamie Morton

MBBS, PhD, FRACP, FCSANZ

Cardiovascular Imaging Specialist

Works at 6 centres.

Dr Peter Purnell

M.B.B.S. (UWA) F.R.A.C.P. F.C.S.A.N.Z

Cardiovascular Imaging Specialist

Joondalup – Shenton House (Cardiology)

Dr David Di Fiore

MBBS, FRACP, FCSANZ

Interventional Cardiologist

Works at 5 centres.

Location